Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner
Molecular Therapy: Oncology
· Elsevier
Аннотация
Publication date: 17 September 2026 Source: Molecular Therapy Oncology, Volume 34, Issue 3 Author(s): Lorenz Hanesch, Nina Hartmann, Sonja Glauß, Tianle Feng, Jennifer Altomonte
Читать у издателя →
Цитирование
Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner. // Molecular Therapy: Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2950329926001621?dgcid=rss_sd_all
Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner. Molecular Therapy: Oncology. https://www.sciencedirect.com/science/article/pii/S2950329926001621?dgcid=rss_sd_all
“Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner.” Molecular Therapy: Oncology.
@article{article117398,
title = {Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner},
journal = {Molecular Therapy: Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2950329926001621?dgcid=rss_sd_all}
}